| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/27/2006 | WO2005099755A3 Methods of treating autoimmune and inflammatory diseases |
| 04/27/2006 | US20060089674 Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| 04/27/2006 | US20060089497 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions |
| 04/27/2006 | US20060089401 Kinase inhibitors |
| 04/27/2006 | US20060089395 Nf-kb activation inhibitors |
| 04/27/2006 | US20060089393 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 04/27/2006 | US20060089379 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 04/27/2006 | US20060089353 Indole derivative compounds and drugs containing the compounds as the active ingredient |
| 04/27/2006 | US20060089345 Indole derivatives, method for preparating same and pharmaceutical compositions containing same |
| 04/27/2006 | US20060089344 E.g., 2-(Methylamino)-2-oxoethyl 3-[1-(1-isoquinolyl)-4-piperidyl]propylcarbamate hydrochloride and 3{2-[1-(2-quinolyl)-4-piperidyl]-ethyl}-1,3-oxazolidine-2,4-dione; preventing or treating a pathology in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FA; analgesics |
| 04/27/2006 | US20060089334 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 04/27/2006 | US20060089326 Immunostimulatory nucleic acid molecules |
| 04/27/2006 | US20060089312 Protease inhibitors |
| 04/27/2006 | US20060089299 Selective treatment of endothelial somatostatin receptors |
| 04/27/2006 | US20060088915 A G protein-coupled receptor protein for the treatment of digestive diseases |
| 04/27/2006 | US20060088890 Identification and isolation of somatic stem cells and uses thereof |
| 04/27/2006 | US20060088561 solidifying agent consists of long chain fatty alcohol; carrier is semi-solid at rest and liquefies upon application of shear forces |
| 04/27/2006 | US20060088545 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therary of diseases associated therewith |
| 04/27/2006 | US20060088542 Imidazoquinoline adjuvants for vaccines |
| 04/27/2006 | US20060088540 Antagonists and methods for inhibiting angiogenesis |
| 04/27/2006 | US20060088529 Bispecific monoclonal antibodies to IL-12 and IL-18 |
| 04/27/2006 | US20060088526 Humanized anti-CD3 specific antibodies |
| 04/27/2006 | US20060088520 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 04/27/2006 | US20060088516 Synthetic peptide combinations and methods of producing same |
| 04/27/2006 | US20060088513 Antiallergic composition |
| 04/27/2006 | US20060088508 Method for obtaining characterized muscle-derived cell populations and uses |
| 04/27/2006 | DE102004050111A1 New active substances (e.g. 1-methyl-DL-tryptophan) are indolamine-2,3-dioxygenase enzyme inhibitors useful for the treatment of curative diseases such as cancer, local immune tolerance and/or suppressions and arteriosclerosis |
| 04/27/2006 | CA2584610A1 Novel dicarboxylic acid derivatives |
| 04/27/2006 | CA2584209A1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 04/27/2006 | CA2583937A1 Chimeric protein |
| 04/27/2006 | CA2583576A1 Chimera (double) decoy |
| 04/27/2006 | CA2574518A1 Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine |
| 04/26/2006 | EP1650304A2 Cloning and recombinant production of vespid venom phospholipase and immunological therapies based thereon |
| 04/26/2006 | EP1650266A1 Product of coprecipitation of sparingly soluble substance and water-soluble polymer and process for producing the same |
| 04/26/2006 | EP1650225A1 Hetero type pentamer recombinant vaccine |
| 04/26/2006 | EP1650205A1 Cyclohexanecarboxylic acid compound |
| 04/26/2006 | EP1650199A1 Sulfonamide derivative having isoxazole ring |
| 04/26/2006 | EP1650193A2 6-Phenylphenanthridines with PDE-IV inhibiting activity |
| 04/26/2006 | EP1650186A1 Novel dicarboxylic acid derivatives |
| 04/26/2006 | EP1649870A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/26/2006 | EP1649856A2 Use of pimecrolimus for selective immunomodulation |
| 04/26/2006 | EP1648868A1 Hydroxamate sulfonamides as cd23 shedding inhibitors |
| 04/26/2006 | EP1648498A1 Microsome vaccine |
| 04/26/2006 | EP1648494A2 Novel anti-angiogenetic agent and its use, in particular in cancer treatment |
| 04/26/2006 | EP1648452A1 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors |
| 04/26/2006 | EP1448281A4 Therapeutic coating for an intravascular implant |
| 04/26/2006 | EP1421377B1 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 04/26/2006 | EP1409485B1 Immunomodulating compounds |
| 04/26/2006 | EP1326634B1 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 04/26/2006 | EP1309592B1 Substituted pyrazoles |
| 04/26/2006 | EP1303286B1 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 04/26/2006 | EP1218514B1 Designing immunogens |
| 04/26/2006 | EP1002108B1 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment |
| 04/26/2006 | EP0811057B1 Viral preparations, vectors, immunogens, and vaccines |
| 04/26/2006 | CN1764655A Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 04/26/2006 | CN1764471A Use of chemokine receptor agonists for stem cell transplantation |
| 04/26/2006 | CN1764459A Oral formulations |
| 04/26/2006 | CN1764455A Pharmaceutical composition comprising a macrolide immunomodulator. |
| 04/26/2006 | CN1764454A Cyclic protein tyrosine kinase inhibitors |
| 04/26/2006 | CN1763097A Polypeptide variants with altered effector function |
| 04/26/2006 | CN1762456A Medicine for improving female estrogen and immunity |
| 04/26/2006 | CN1762399A American ginseng effervescence tablet and its preparation method |
| 04/26/2006 | CN1762391A Cow colostrums and lentinus edodes extracts composition, its preparation method and application |
| 04/26/2006 | CN1762365A Beta-carotene clathrate and its preparation method |
| 04/26/2006 | CN1762360A Compound cetirizine hydrochloride gel |
| 04/26/2006 | CN1762359A Lindera root alkaloid, its preparation method and application in medicine preparation |
| 04/26/2006 | CN1253528C Desiccation compositions containing hydrophobic amino acid |
| 04/26/2006 | CN1253471C Type CC chemokine-like protein |
| 04/26/2006 | CN1253470C Treatment of inflammatory disease |
| 04/26/2006 | CN1253452C Thioether subsituted imidazoquinoline compound |
| 04/26/2006 | CN1253449C Indolylmaleimide derivatives as protein kinase C inibitors |
| 04/26/2006 | CN1253435C Aryl oxime-piperazines useful as CCR5 antagonists |
| 04/26/2006 | CN1253220C Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 04/26/2006 | CN1253208C Use of antibodies against CD2O for treatment of graft versus host disease |
| 04/26/2006 | CN1253206C Method for obtaining antigenic aggregates and use thereof in formulations |
| 04/26/2006 | CN1253172C Anti-allergic agents, drugs, foods, or cosmetics containing them and process for producing the same |
| 04/26/2006 | CN1253159C Health product of compound propolis and preparing method |
| 04/25/2006 | US7034153 Antidepressants; anxiolytic agents; eating disorders; antiulcer agents; drug abuse; Alzheimer's disease |
| 04/25/2006 | US7034141 The packaging systems are based on the expression of split-helper functions by coinfecting cells with recombinant vectors, such as recombinant poxvirus vectors |
| 04/25/2006 | US7034131 Antibody therapy; immobilization |
| 04/25/2006 | US7034121 Antibodies against CTLA4 |
| 04/25/2006 | US7034057 Controlling tumor necrosis factor; antiinflamamtory agents, autoimmune disease |
| 04/25/2006 | US7034049 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 04/25/2006 | US7034043 Cell adhesion inhibitors |
| 04/25/2006 | US7034042 Corticotropin releasing factor receptor antagonist |
| 04/25/2006 | US7034031 Modulators of TNF-α signaling |
| 04/25/2006 | US7034028 Treatment of inflammatory disorders |
| 04/25/2006 | US7034025 Administering to a mammal an effective dose of a cysteine derivatives containing heteroaromatic group for the treatment of arterial tension, embryogenesis, oncogenesis, diabetes, cell proliferation, and other diseases |
| 04/25/2006 | US7034018 Substituted pyrrole mannich bases to combat pain and allergic reactions |
| 04/25/2006 | US7034016 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives |
| 04/25/2006 | US7034006 Use of lipid conjugates in the treatment of disease |
| 04/25/2006 | US7033794 Basolateral sorting signal and inhibitors thereof |
| 04/25/2006 | US7033605 performing an ocular transplant procedure; implanting in the eye a biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer. |
| 04/25/2006 | US7033604 Composition for topical administration |
| 04/25/2006 | US7033594 Method of treatment using ligand-immunogen conjugates |
| 04/25/2006 | US7033591 use of a membrane fraction of gram-negative bacteria such as Klebsiella pnemoniae comprising proteoglycans in combination with anticancer treatment for immunostimulant and/or inducing an antitumor immune response in mammals including humans |
| 04/25/2006 | US7033583 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials |
| 04/25/2006 | US7033575 Delivery of physiologically active compounds through an inhalation route |
| 04/25/2006 | CA2438097C Cannabinoids pharmaceutical formulations |
| 04/25/2006 | CA2194885C Substituted benzamidines, their preparation and their use as pharmaceutical compounds |